Stockscreener 앱 받기
39.06
5.79%
-2.40
전일 마감가:
$41.46
열려 있는:
$41.19
하루 거래량:
728.31K
Relative Volume:
1.37
시가총액:
$1.94B
수익:
$499.95M
순이익/손실:
$-36.36M
주가수익비율:
-50.73
EPS:
-0.77
순현금흐름:
$24.22M
1주 성능:
-5.79%
1개월 성능:
-4.92%
6개월 성능:
+28.57%
1년 성능:
+3.77%
1일 변동 폭
$38.93
$41.80
1주일 범위
$36.06
$41.95
52주 변동 폭
$28.29
$43.18
Atricure Inc Stock (ATRC) Company Profile
명칭
Atricure Inc
전화
513-755-4100
주소
7555 INNOVATION WAY, MASON, OH
ATRC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATRC
Atricure Inc
|
39.06 | 2.06B | 499.95M | -36.36M | 24.22M | -0.77 |
|
ISRG
Intuitive Surgical Inc
|
535.00 | 191.90B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
207.11 | 59.36B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
79.00 | 39.13B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
257.58 | 38.05B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
MDLN
Medline Inc
|
44.12 | 33.62B | 27.43B | 1.27B | 1.01B | 1.5829 |
Atricure Inc Stock (ATRC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-17 | 재개 | JP Morgan | Overweight |
| 2024-04-23 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-10-23 | 개시 | JMP Securities | Mkt Outperform |
| 2023-09-29 | 개시 | UBS | Buy |
| 2021-08-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-12-18 | 재확인 | Needham | Buy |
| 2020-11-06 | 재확인 | Needham | Buy |
| 2020-04-07 | 개시 | Oppenheimer | Outperform |
| 2020-02-06 | 개시 | BTIG Research | Buy |
| 2020-01-24 | 재확인 | Needham | Buy |
| 2019-08-13 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2019-04-12 | 개시 | JP Morgan | Overweight |
| 2018-10-04 | 재확인 | Needham | Buy |
| 2018-08-02 | 재확인 | Needham | Buy |
| 2018-08-02 | 재확인 | Stifel | Buy |
| 2018-06-18 | 재확인 | Needham | Buy |
| 2018-04-27 | 재확인 | Needham | Buy |
| 2018-01-16 | 재확인 | Needham | Buy |
| 2017-11-02 | 재확인 | Needham | Buy |
| 2017-07-28 | 재확인 | Needham | Buy |
| 2017-05-30 | 재개 | Piper Jaffray | Overweight |
| 2016-06-30 | 재개 | JMP Securities | Mkt Outperform |
| 2015-10-28 | 재확인 | Needham | Buy |
| 2015-10-06 | 재확인 | Canaccord Genuity | Buy |
| 2015-10-06 | 재확인 | Needham | Buy |
모두보기
Atricure Inc 주식(ATRC)의 최신 뉴스
AtriCure (ATRC) Is Down 5.8% After Issuing 2026 Profitability Guidance And Expanding Credit Facility - Yahoo Finance
What are AtriCure Incs recent SEC filings showingMarket Growth Review & Long-Term Safe Return Strategies - baoquankhu1.vn
Intuitive Surgical Stock Dips on Q4 Preliminary Revenue Results - Your Wyoming Link
AtriCure Stock (+11%): Profitability Inflection Ignites Re-Rate - Trefis
AtriCure (NASDAQ:ATRC) Trading 6.7% HigherHere's Why - MarketBeat
AtriCure Inc (ATRC) Shares Up 8.49% on Jan 15 - GuruFocus
AtriCure CEO Touts $10B AFib and Pain Market, Raises EBITDA Outlook at JPMorgan Conference - MarketBeat
ATRC: Innovation and clinical evidence drive growth in AFib and pain management, with strong financial results - TradingView — Track All Markets
Atricure (ATRC) Receives a Buy from Canaccord Genuity - The Globe and Mail
Street Watch: What is AtriCure Incs revenue forecastBear Alert & Low Risk Investment Opportunities - baoquankhu1.vn
AtriCure reports 13% revenue growth in Q4 2025, provides 2026 outlook - Investing.com Nigeria
AtriCure, Inc. (ATRC) Investor Outlook: Analyzing A 40% Potential Upside - DirectorsTalk Interviews
AtriCure (NASDAQ:ATRC) Shares Down 7.6%Time to Sell? - MarketBeat
AtriCure, Inc. and AtriCure, LLC Enter into a First Amendment to Credit Agreement - marketscreener.com
ATRC: Projected Strong Revenue and Growth by 2026 - GuruFocus
AtriCure (NASDAQ:ATRC) Releases Q4 2025 Earnings Guidance - MarketBeat
AtriCure (ATRC) Anticipates Strong Revenue Growth in Q4 2025 - GuruFocus
AtriCure's preliminary Q4 revenue rises 13%, slightly beats estimates - TradingView — Track All Markets
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026 - Yahoo Finance
AtriCure Reports Strong Preliminary 2025 Revenue Growth - TipRanks
AtriCure IncEnters first amendment to credit agreementSEC filing - marketscreener.com
AtriCure Signs First Amendment to Credit Agreement With JPMorgan Chase Bank - TradingView — Track All Markets
A Look At AtriCure (ATRC) Valuation As Earnings Beats And Analyst Optimism Lift Confidence - simplywall.st
Jobs Data: Why is AtriCure Inc stock going down2025 Fundamental Recap & Stock Portfolio Risk Management - baoquankhu1.vn
AtriCure, Inc. (ATRC) soars to 52-week high, time to cash out? - MSN
Will AtriCure Inc. stock benefit from green energy trendsJuly 2025 Intraday Action & Risk Controlled Daily Trade Plans - Улправда
(ATRC) Movement as an Input in Quant Signal Sets - Stock Traders Daily
AtriCure, Inc. (ATRC) Soars to 52-Week High, Time to Cash Out? - Yahoo Finance
Is AtriCure Inc. stock a defensive play in 2025July 2025 Movers & Fast Gaining Stock Strategy Reports - Улправда
Will AtriCure Inc. stock benefit from automationJuly 2025 Short Interest & High Return Trade Guides - Улправда
Will AtriCure Inc. stock continue upward momentumQuarterly Risk Review & AI Powered Trade Plan Recommendations - Улправда
Will AtriCure Inc. stock attract ESG investorsJuly 2025 Breakouts & High Accuracy Trade Alerts - Улправда
AtriCure (NASDAQ:ATRC) Reaches New 12-Month HighWhat's Next? - MarketBeat
AtriCure stock hits 52-week high at $43.18 By Investing.com - Investing.com Canada
AtriCure stock hits 52-week high at $43.18 - Investing.com
Fed Watch: How risky is AtriCure Inc. stock nowJuly 2025 Earnings & Comprehensive Market Scan Insights - Улправда
Is AtriCure Inc. stock trading at a premium valuation2025 Earnings Impact & Community Trade Idea Sharing Platform - Улправда
AtriCure (NASDAQ:ATRC) Upgraded at Zacks Research - MarketBeat
AtriCure (NASDAQ:ATRC) Share Price Crosses Above 200-Day Moving AverageShould You Sell? - MarketBeat
AtriCure, Inc. (NASDAQ:ATRC) Nasdaq Index Fund Medical Devices - Kalkine Media
AtriCure Inc (ATRC) Product Pipeline Analysis Report 2025: Portfolio Led by Isolator Synergy, AtriCl - PharmiWeb.com
AtriCure Inc (ATRC) Product Pipeline Analysis Report 2025: Portfolio Led by Isolator Synergy, AtriClip, Hybrid AF Therapy, and cryoICE cryoSPHERE TechnologiesResearchAndMarkets.com - The AI Journal
About Us - FinancialContent
Liquidity Mapping Around (ATRC) Price Events - Stock Traders Daily
AtriCure (ATRC): Assessing Valuation After First-In-Human PFA/RFA Procedures and Renewed Analyst Optimism - Yahoo Finance
Assessing AtriCure’s Valuation After a 33.4% Rally in 2025 - Yahoo Finance
AtriCure, Inc. (NASDAQ:ATRC) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Has AtriCure (ATRC) Outpaced Other Medical Stocks This Year? - sharewise.com
AtriCure (NASDAQ:ATRC) Stock Crosses Above Two Hundred Day Moving AverageHere's Why - MarketBeat
AtriCure Inc (NASDAQ:ATRC) Nasdaq Index Medical Device Depth - Kalkine Media
What AtriCure (ATRC)'s First Dual-Energy PFA–RFA Procedures Mean For Shareholders - Sahm
Atricure Inc (ATRC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.01%
1.19%
자본화:
|
볼륨(24시간):